WO2022255378A1 - 皮膚表上脂質検体内部標準遺伝子 - Google Patents
皮膚表上脂質検体内部標準遺伝子 Download PDFInfo
- Publication number
- WO2022255378A1 WO2022255378A1 PCT/JP2022/022187 JP2022022187W WO2022255378A1 WO 2022255378 A1 WO2022255378 A1 WO 2022255378A1 JP 2022022187 W JP2022022187 W JP 2022022187W WO 2022255378 A1 WO2022255378 A1 WO 2022255378A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- internal standard
- genes
- pcr
- expression level
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 335
- 150000002632 lipids Chemical class 0.000 title claims abstract description 20
- 230000014509 gene expression Effects 0.000 claims abstract description 95
- 238000000034 method Methods 0.000 claims abstract description 94
- 108010016281 ADP-Ribosylation Factor 1 Proteins 0.000 claims description 17
- 101000732045 Homo sapiens FAU ubiquitin-like and ribosomal protein S30 Proteins 0.000 claims description 17
- 101001089120 Homo sapiens Proteasome subunit beta type-3 Proteins 0.000 claims description 17
- 101000840051 Homo sapiens Ubiquitin-60S ribosomal protein L40 Proteins 0.000 claims description 17
- 102100033755 Proteasome subunit beta type-3 Human genes 0.000 claims description 17
- 102100028462 Ubiquitin-60S ribosomal protein L40 Human genes 0.000 claims description 17
- 102100034341 ADP-ribosylation factor 1 Human genes 0.000 claims description 16
- 102100034003 FAU ubiquitin-like and ribosomal protein S30 Human genes 0.000 claims description 15
- 102100024113 40S ribosomal protein S15a Human genes 0.000 claims description 14
- 102100022048 60S ribosomal protein L36 Human genes 0.000 claims description 14
- 101150073167 Eif1 gene Proteins 0.000 claims description 14
- 102100029775 Eukaryotic translation initiation factor 1 Human genes 0.000 claims description 14
- 101001118566 Homo sapiens 40S ribosomal protein S15a Proteins 0.000 claims description 14
- 101001110263 Homo sapiens 60S ribosomal protein L36 Proteins 0.000 claims description 14
- 101000802734 Homo sapiens eIF5-mimic protein 2 Proteins 0.000 claims description 14
- 102100035859 eIF5-mimic protein 2 Human genes 0.000 claims description 14
- 230000003321 amplification Effects 0.000 claims description 11
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 11
- 102100037663 40S ribosomal protein S8 Human genes 0.000 claims description 10
- 102100025643 60S ribosomal protein L12 Human genes 0.000 claims description 10
- 102100038237 60S ribosomal protein L30 Human genes 0.000 claims description 10
- 102100022890 ATP synthase subunit beta, mitochondrial Human genes 0.000 claims description 10
- 102100023362 Elongation factor 1-gamma Human genes 0.000 claims description 10
- 101001097439 Homo sapiens 40S ribosomal protein S8 Proteins 0.000 claims description 10
- 101000575173 Homo sapiens 60S ribosomal protein L12 Proteins 0.000 claims description 10
- 101001101319 Homo sapiens 60S ribosomal protein L30 Proteins 0.000 claims description 10
- 101000903027 Homo sapiens ATP synthase subunit beta, mitochondrial Proteins 0.000 claims description 10
- 101001050451 Homo sapiens Elongation factor 1-gamma Proteins 0.000 claims description 10
- 101001003310 Homo sapiens Immediate early response gene 5 protein Proteins 0.000 claims description 10
- 101000594698 Homo sapiens Ornithine decarboxylase antizyme 1 Proteins 0.000 claims description 10
- 101000735358 Homo sapiens Poly(rC)-binding protein 2 Proteins 0.000 claims description 10
- 102100020688 Immediate early response gene 5 protein Human genes 0.000 claims description 10
- 108091034117 Oligonucleotide Proteins 0.000 claims description 10
- 102100036199 Ornithine decarboxylase antizyme 1 Human genes 0.000 claims description 10
- 102100034961 Poly(rC)-binding protein 2 Human genes 0.000 claims description 10
- 102100024841 Protein BRICK1 Human genes 0.000 claims description 10
- 101710084314 Protein BRICK1 Proteins 0.000 claims description 10
- 102100025007 14-3-3 protein epsilon Human genes 0.000 claims description 7
- 102100037513 40S ribosomal protein S23 Human genes 0.000 claims description 7
- 102100022406 60S ribosomal protein L10a Human genes 0.000 claims description 7
- 102100021690 60S ribosomal protein L18a Human genes 0.000 claims description 7
- 102100031002 60S ribosomal protein L36a Human genes 0.000 claims description 7
- 102100026926 60S ribosomal protein L4 Human genes 0.000 claims description 7
- 102100028357 ADP-ribosylation factor-like protein 8B Human genes 0.000 claims description 7
- 102100032403 Charged multivesicular body protein 1b Human genes 0.000 claims description 7
- 101000760079 Homo sapiens 14-3-3 protein epsilon Proteins 0.000 claims description 7
- 101001097953 Homo sapiens 40S ribosomal protein S23 Proteins 0.000 claims description 7
- 101000755323 Homo sapiens 60S ribosomal protein L10a Proteins 0.000 claims description 7
- 101000752293 Homo sapiens 60S ribosomal protein L18a Proteins 0.000 claims description 7
- 101001127203 Homo sapiens 60S ribosomal protein L36a Proteins 0.000 claims description 7
- 101001127258 Homo sapiens 60S ribosomal protein L36a-like Proteins 0.000 claims description 7
- 101000691203 Homo sapiens 60S ribosomal protein L4 Proteins 0.000 claims description 7
- 101000769042 Homo sapiens ADP-ribosylation factor-like protein 8B Proteins 0.000 claims description 7
- 101000990986 Homo sapiens Myosin regulatory light chain 12A Proteins 0.000 claims description 7
- 101000591187 Homo sapiens Notch homolog 2 N-terminal-like protein A Proteins 0.000 claims description 7
- 101000735354 Homo sapiens Poly(rC)-binding protein 1 Proteins 0.000 claims description 7
- 101000919019 Homo sapiens Probable ATP-dependent RNA helicase DDX6 Proteins 0.000 claims description 7
- 101000584785 Homo sapiens Ras-related protein Rab-7a Proteins 0.000 claims description 7
- 101000832685 Homo sapiens Small ubiquitin-related modifier 2 Proteins 0.000 claims description 7
- 101000740275 Homo sapiens Store-operated calcium entry-associated regulatory factor Proteins 0.000 claims description 7
- 101100274086 Mus musculus Chmp1b1 gene Proteins 0.000 claims description 7
- 102100030329 Myosin regulatory light chain 12A Human genes 0.000 claims description 7
- 102100034093 Notch homolog 2 N-terminal-like protein A Human genes 0.000 claims description 7
- 102100034960 Poly(rC)-binding protein 1 Human genes 0.000 claims description 7
- 102100029480 Probable ATP-dependent RNA helicase DDX6 Human genes 0.000 claims description 7
- 102100030019 Ras-related protein Rab-7a Human genes 0.000 claims description 7
- 102100024542 Small ubiquitin-related modifier 2 Human genes 0.000 claims description 7
- 102100037172 Store-operated calcium entry-associated regulatory factor Human genes 0.000 claims description 7
- 101150049218 chmp1b gene Proteins 0.000 claims description 7
- 102100021927 60S ribosomal protein L27a Human genes 0.000 claims description 4
- 102100021671 60S ribosomal protein L29 Human genes 0.000 claims description 4
- 102100027992 Casein kinase II subunit beta Human genes 0.000 claims description 4
- 101000753696 Homo sapiens 60S ribosomal protein L27a Proteins 0.000 claims description 4
- 101000676246 Homo sapiens 60S ribosomal protein L29 Proteins 0.000 claims description 4
- 101000858625 Homo sapiens Casein kinase II subunit beta Proteins 0.000 claims description 4
- 101001068219 Homo sapiens Serine/threonine-protein phosphatase 4 catalytic subunit Proteins 0.000 claims description 4
- 101000663444 Homo sapiens Transcription elongation factor SPT4 Proteins 0.000 claims description 4
- 102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 claims description 4
- 102100034492 Serine/threonine-protein phosphatase 4 catalytic subunit Human genes 0.000 claims description 4
- 102100038997 Transcription elongation factor SPT4 Human genes 0.000 claims description 4
- 108010062302 rac1 GTP Binding Protein Proteins 0.000 claims description 4
- 238000000691 measurement method Methods 0.000 claims 2
- 239000000047 product Substances 0.000 description 47
- 239000000523 sample Substances 0.000 description 47
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 39
- 238000003753 real-time PCR Methods 0.000 description 34
- 108020004414 DNA Proteins 0.000 description 31
- 210000003491 skin Anatomy 0.000 description 26
- 238000011002 quantification Methods 0.000 description 23
- 239000002299 complementary DNA Substances 0.000 description 13
- 238000010839 reverse transcription Methods 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 108700039887 Essential Genes Proteins 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 238000010606 normalization Methods 0.000 description 9
- 102000053602 DNA Human genes 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 102100040881 60S acidic ribosomal protein P0 Human genes 0.000 description 7
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 7
- 101000673456 Homo sapiens 60S acidic ribosomal protein P0 Proteins 0.000 description 7
- 102100034343 Integrase Human genes 0.000 description 7
- 238000012408 PCR amplification Methods 0.000 description 7
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 238000010195 expression analysis Methods 0.000 description 7
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 6
- 210000002374 sebum Anatomy 0.000 description 6
- 238000011088 calibration curve Methods 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 238000007403 mPCR Methods 0.000 description 5
- -1 1B15 Proteins 0.000 description 4
- 238000002123 RNA extraction Methods 0.000 description 4
- 239000002250 absorbent Substances 0.000 description 4
- 230000002745 absorbent Effects 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 3
- 239000000138 intercalating agent Substances 0.000 description 3
- 239000012264 purified product Substances 0.000 description 3
- 210000001732 sebaceous gland Anatomy 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000012232 AGPC extraction Methods 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000010805 cDNA synthesis kit Methods 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 210000000106 sweat gland Anatomy 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000003021 water soluble solvent Substances 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000007847 digital PCR Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2545/00—Reactions characterised by their quantitative nature
- C12Q2545/10—Reactions characterised by their quantitative nature the purpose being quantitative analysis
- C12Q2545/101—Reactions characterised by their quantitative nature the purpose being quantitative analysis with an internal standard/control
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
Definitions
- the present invention relates to an internal standard gene for lipid samples on the skin surface and a method for measuring gene expression level using the same.
- the PCR method is widely used. Quantitative analysis of the expression level of a target gene by real-time PCR is roughly divided into absolute quantification and relative quantification.
- the absolute quantification method is a technique in which a calibration curve is prepared from a standard sample whose absolute amount such as copy number is known, and the absolute amount of expression of the target gene in the sample is quantified using this curve.
- the relative quantification method is a method of correcting the expression level of the target gene in the sample with the expression level of the internal standard gene, and quantifying the relative expression level of the target gene.
- Non-Patent Documents 1 and 2 It is important that the internal standard gene is a gene whose expression level does not vary between tissues or between experimental systems, and housekeeping genes such as GAPDH and ACTB are generally used. However, it has been reported that even housekeeping genes may not function as internal standard genes due to tissue-dependent variations in expression (Non-Patent Documents 1 and 2).
- Patent Document 1 discloses that skin surface lipids (SSL) contain RNA derived from the skin cells of a subject, and that the RNA contained in SSL is used as a sample for gene expression analysis in vivo. and that marker genes of epidermis, sweat glands, hair follicles and sebaceous glands can be detected from SSL.
- SSL skin surface lipids
- Patent Document 1 International Publication No. 2018/008319 (Non-Patent Document 1) Journal of Investigative Dermatology, 2009, 129(3):535-537 (Non-Patent Document 2) Acta Biochem Biophys Sin, 2014, 46(4):330-337 (Non-Patent Document 3) Journal of Investigative Dermatology, 2009, 129(3):770-773
- the present invention relates to the following (1) to (3).
- a method for measuring the expression level of a target gene contained in an SSL sample which comprises using at least one gene selected from the group consisting of the genes shown in Table 1 below as an internal standard gene in PCR.
- a kit for measuring the expression level of the target gene contained in the SSL sample used in the method (1) which contains an oligonucleotide that specifically hybridizes with the internal standard gene.
- nucleic acid means DNA or RNA.
- DNA includes cDNA, genomic DNA, and synthetic DNA
- RNA includes total RNA, mRNA, rRNA, tRNA, non-coding RNA, and synthetic RNA.
- the term "gene” refers to double-stranded DNA containing human genomic DNA, single-stranded DNA (positive strand) containing cDNA, and single-stranded DNA (complementary strand) having a sequence complementary to the positive strand. strands), and fragments thereof, which contain some biological information in the sequence information of the bases that make up the DNA.
- the “gene” includes not only “gene” represented by a specific nucleotide sequence, but also nucleic acids encoding their homologues (i.e., homologues or orthologs), variants such as polymorphisms, and derivatives. be done.
- the names (Gene Symbols) and Gene IDs of the genes disclosed herein follow the Official Symbols and Gene IDs described in NCBI ([www.ncbi.nlm.nih.gov/]).
- the term "internal standard gene” is also referred to as an endogenous control gene or reference gene, and means a gene that serves as a standard for correcting (standardizing) the expression level of a target gene in gene expression analysis. "Correction” is typically performed by dividing the expression level of the target gene by the expression level of the internal standard gene. “Expression level” or “amount” includes the absolute amount of expression and the relative expression level with respect to the expression level of other genes and the like.
- the term “housekeeping gene” means a gene that is essential for the maintenance and growth of cells and that is commonly expressed in many tissues and cells at a certain level. As general housekeeping genes, for example, GAPDH, ACTB and the like are known (see Genome Analysis, 2003, 19(7):362-365).
- SSL skin surface lipids
- skin is a general term for areas including stratum corneum, epidermis, dermis, hair follicles, and tissues such as sweat glands, sebaceous glands and other glands.
- the present invention relates to providing an internal standard gene for more accurately measuring the expression level of a target gene contained in SSL, and a method for measuring the expression level of the target gene contained in SSL using the internal standard gene.
- the internal standard gene of the present invention has small expression fluctuations between SSL samples, and particularly small expression fluctuations compared to GAPDH and ACTB, which are known housekeeping genes generally used as internal standard genes.
- GAPDH and ACTB housekeeping genes generally used as internal standard genes.
- the 52 genes shown in Table 1 of the present invention are genes found to exhibit small fluctuations in the expression level of SSL-derived RNA between subjects, as shown in Examples described later.
- the 52 genes shown in Table 1 represent the expression levels of RNA extracted from the SSL of a total of 1953 subjects, 803 healthy males (hereinafter also simply referred to as males) and 1150 healthy females (hereinafter simply referred to as females). Divide the data (read count value) into three types of data sets for men, women, and men and women (hereinafter referred to as the men's data set, the women's data set, and the men's and women's data sets) , Using two normalization methods, the Log2 RPM method and the RLE method, the gene detection rate is 80% or more (Log2 RPM method) or 90% or more (RLE method) for each data set.
- CV Z-score indicates the deviation of the measured value from the mean value of the distribution, normalizing the coefficient of variation (CV) calculated by dividing the difference between the measured value and the mean value of the distribution by the standard deviation of the distribution It is a value (Z-score) obtained as a result, and the smaller the value of CV Z-score, the smaller the variation in gene expression (the average value of CV Z-score itself is 0, the standard deviation is 1 is).
- the average value of the CV Z-scores of the two normalization methods (hereinafter referred to as the CV Z-score based on the two normalization methods) is used as an evaluation index for expression stability, which is ⁇ 1.11.
- the following genes were determined to be stably expressed genes.
- the above 52 genes are known housekeeping genes, GAPDH and ACTB, which are generally suitable as internal standard genes, and also as internal standard genes in gene expression analysis of epidermal keratinocytes.
- the CV Z-score was comparable or lower compared to the preferred RPLP0, confirming stable expression in SSL.
- a gene selected from the group consisting of such 52 genes is used as an internal standard gene (hereinafter also referred to as the internal standard gene of the present invention) in qPCR when measuring the expression level of the target gene contained in SSL.
- an internal standard gene hereinafter also referred to as the internal standard gene of the present invention
- any one gene may be used alone, or two or more genes may be used in combination.
- CV Z-score indicates the mean value of CV Z-score based on two normalization methods in each of all three data sets.
- the 19 genes in Table 3 (Tables 3-1 and 3-2) are genes stably expressed in common in any two of the three datasets. 12 genes are stably expressed genes in common in the male dataset and male and female datasets, and 7 genes in Table 3-2 are common in the female dataset and male and female datasets. It is a gene that is stably expressed as In Table 3, CV Z-score indicates the mean value of CV Z-scores based on the two normalization methods for each of the two corresponding data sets.
- the 4 genes in Table 4 are genes that are stably expressed in one of the three datasets, and the 2 genes in Table 4-1 are , are stably expressed genes in the male dataset, and 2 genes in Table 4-2 are stably expressed genes in the male and female datasets.
- CV Z-score indicates the CV Z-score based on the two normalization methods in the relevant dataset.
- the internal standard gene of the present invention is preferably at least one gene selected from the group consisting of the genes shown in Tables 2 and 3, more preferably at least one gene selected from the group consisting of the genes shown in Table 2.
- 1 gene more preferably selected from the group consisting of 15 genes of FAU, ARF1, RPS8, RPL30, UBA52, RPL10A, RAB7A, PSMB3, RPL36, EIF1, RAC1, RPL29, CSNK2B, RPS15A, and BZW1 at least one gene, more preferably at least one gene selected from the group consisting of the 8 genes of FAU, ARF1, RPS8, RPL30, UBA52, RPL10A, RAB7A, and PSMB3, more preferably FAU, At least one gene selected from the group consisting of the four genes ARF1, RPS8 and RPL30, more preferably at least one gene selected from the two genes FAU and ARF1.
- the internal standard gene of the present invention is preferably at least one gene selected from the group consisting of the above 29 genes, more preferably UBA52, PSMB3, RPL36, EIF1, RPS15A, BZW1, selected from the group consisting of 26 genes of OAZ1, ATP5B, BRK1, EEF1G, PCBP2, RPL12, IER5, ARL8B, PCBP1, RPL4, TMEM66, SUMO2, RPS23, NOTCH2NL, RPL36A, CHMP1B, MYL12A, RPL18A, DDX6, and YWHAE
- At least one gene, more preferably at least one selected from the group consisting of 13 genes of UBA52, PSMB3, RPL36, EIF1, RPS15A, BZW1, OAZ1, ATP5B, BRK1, EEF1G, PCBP2, RPL12, and IER5 is the gene for
- the internal standard gene of the present invention also includes genes having substantially the same base sequence as the base sequence of the DNA that constitutes the gene, as long as it can serve as an internal standard in gene expression analysis.
- the internal standard gene of the present invention is suitably used in a method for measuring the expression level of a target gene contained in an SSL sample (hereinafter also referred to as the method of the present invention).
- the method of the present invention includes calculating the expression level of the target gene by correcting the amount of the amplified product of the target gene with the amount of the amplified product of the internal standard gene for the SSL sample.
- the method of the present invention comprises amplifying the target gene, amplifying the internal standard gene, and correcting the amount of the target gene amplification product with the amount of the internal standard gene amplification product for the SSL sample. and calculating the expression level of the target gene.
- the method of the present invention comprises: extracting RNA from a lipid sample on the skin surface collected from a subject; amplifying a target gene based on the extracted RNA; Amplifying an internal standard gene based on the above, correcting the amount of the amplified product of the target gene with the amount of the amplified product of the internal standard gene, and calculating the expression level of the target gene.
- the target gene is not particularly limited as long as it is a gene that can be contained in an SSL sample, and may be one or two or more.
- the subject from which SSL is collected may be any organism that has SSL on its skin.
- subjects include mammals, including humans and non-human mammals, preferably humans.
- the subject is a human or non-human mammal, more preferably a human, that requires or desires analysis of its own nucleic acids.
- any means used to collect or remove SSL from the skin can be used to collect the SSL from the subject's skin.
- an SSL absorbent material, an SSL adhesive material, or an instrument that scrapes the SSL off the skin can be used.
- the SSL absorbent material or SSL adhesive material is not particularly limited as long as it has affinity for SSL, and examples thereof include polypropylene and pulp. More detailed examples of procedures for collecting SSL from the skin include a method of absorbing SSL into sheet-like materials such as blotting paper and blotting film, a method of adhering SSL to a glass plate, tape, etc., a spatula, a scraper, etc. and a method of scraping off and recovering the SSL.
- an SSL absorbent material previously impregnated with a solvent having high fat solubility may be used.
- the SSL absorptive material contains a highly water-soluble solvent or moisture, the adsorption of SSL is inhibited, so it is preferable that the content of the highly water-soluble solvent and moisture is small.
- the SSL absorbent material is preferably used dry.
- the site of the skin from which the SSL is collected is not particularly limited, and includes any site of the body such as the head, face, neck, trunk, limbs, etc., and sites with high sebum secretion, such as the skin of the face. is preferred.
- the RNA-containing SSL sample collected from the subject may be used immediately for the RNA extraction step described below, or may be stored for a certain period of time. In order to minimize degradation of the RNA contained in the collected SSL specimen, it is preferable to store it under low temperature conditions as soon as possible after collection.
- the temperature condition for storing the RNA-containing SSL in the present invention may be 0°C or lower, preferably -20 ⁇ 20°C to -80 ⁇ 20°C, more preferably -20 ⁇ 10°C to -80 ⁇ 10°C.
- the period of storage of the RNA-containing SSL sample under the low-temperature conditions is not particularly limited, but is preferably 12 months or less, for example, 6 hours or more and 12 months or less, more preferably 6 months or less, for example, 1 day or more and 6 months or less, More preferably, it is 3 months or less, for example, 3 days or more and 3 months or less.
- RNA contained in an SSL specimen is extracted, converted to cDNA by reverse transcription, and the target gene and internal standard gene are amplified by PCR using the cDNA as a template, and then the amplified product is obtained. is measured.
- RNA from SSL For extraction of RNA from SSL, methods commonly used to extract or purify RNA from biological samples, such as the phenol/chloroform method, the AGPC (acid guanidinium thiocyanate-phenol-chloroform extraction) method, or TRIzol® ), a method using a column such as RNeasy (registered trademark), QIAzol (registered trademark), a method using special magnetic particles coated with silica, a method using Solid Phase Reversible Immobilization magnetic particles, a commercially available method such as ISOGEN Extraction with an RNA extraction reagent or the like can be used.
- the AGPC acid guanidinium thiocyanate-phenol-chloroform extraction
- TRIzol® a method using a column such as RNeasy (registered trademark), QIAzol (registered trademark)
- a method using special magnetic particles coated with silica a method using Solid Phase Reversible Immobilization magnetic particles
- primers targeting specific RNAs to be analyzed may be used, but random primers are preferably used for more comprehensive nucleic acid storage and analysis.
- a common reverse transcriptase or reverse transcription reagent kit can be used for the reverse transcription.
- a highly accurate and efficient reverse transcriptase or reverse transcription reagent kit is used, examples of which include M-MLV Reverse Transcriptase and variants thereof, or commercially available reverse transcriptase or reverse transcription reagent kit, Examples include PrimeScript (registered trademark) Reverse Transcriptase series (Takara Bio Inc.) and SuperScript (registered trademark) Reverse Transcriptase series (Thermo Scientific).
- the temperature is preferably adjusted to 42°C ⁇ 1°C, more preferably 42°C ⁇ 0.5°C, even more preferably 42°C ⁇ 0.25°C, while the reaction time is preferably It is preferable to adjust the time to 60 minutes or more, more preferably 80 to 120 minutes.
- Amplification of the target gene or internal standard gene using cDNA obtained by reverse transcription as a template can be carried out according to PCR procedures commonly used in the art.
- PCR techniques include conventional PCR, multiplex PCR, real-time PCR (also referred to as quantitative PCR (quantitative PCR; qPCR)), multiplex real-time PCR, digital PCR, and the like.
- cDNA synthesis (RT) by reverse transcription and PCR may be performed in one step or in two steps, and either one may be appropriately selected depending on the purpose.
- One-step RT-PCR is a series of RT and PCR reactions that are performed consecutively in a single tube, which is very convenient and can prevent contamination during the RT and PCR operations.
- two-step RT-PCR since random primers can be used for RT, expression levels of multiple target genes can be measured from a single RNA specimen. Examples of PCR in RT-PCR include those similar to the PCR described above.
- a primer pair targeting a specific DNA to be analyzed may be used to amplify only the specific DNA, but a plurality of primer pairs may be used to simultaneously amplify a plurality of DNAs.
- Techniques for simultaneously amplifying multiple DNAs include multiplex PCR and multiplex real-time PCR. It is preferable to perform multiplex analysis in which the target gene and the internal standard gene are simultaneously amplified in that errors in the amount of template DNA can be suppressed and the expression level can be measured more accurately.
- Such multiplex analysis can be performed using a commercially available kit (eg, Ion AmpliSeq Transcriptome Human Gene Expression Kit; Life Technologies Japan Co., Ltd., etc.).
- a known means capable of specifically recognizing the amplification product can be used to detect the amplification product.
- a method of detecting labeled double-stranded DNA produced by performing PCR using primers previously labeled with RI, a fluorescent substance, or the like can be used.
- real-time PCR or multiplex real-time PCR which monitors and analyzes the amount of amplified PCR products in real time, is used as a quantitative PCR (qPCR) technique in terms of rapidity, convenience and quantification.
- qPCR quantitative PCR
- Methods for detecting amplification products in real-time PCR or multiplex real-time PCR include methods commonly used in the art, such as the intercalator method and the TaqMan (registered trademark) probe method.
- intercalator a substance that emits fluorescence when it enters the double-stranded DNA (intercalator, for example, SYBR (registered trademark) Green I, etc.) is allowed to coexist in the PCR reaction system, and the fluorescence that increases with the production of the amplified product is emitted. This is a method of monitoring the amount of amplified product by detection.
- intercalator for example, SYBR (registered trademark) Green I, etc.
- TaqMan probe a target sequence-specific oligonucleotide (TaqMan probe) modified at the 5′ end with a fluorescent substance (FAM, etc.) and at the 3′ end with a quencher substance (TAMRA, etc.) coexists in a PCR reaction system.
- FAM fluorescent substance
- TAMRA quencher substance
- the TaqMan probe specifically hybridizes to the template DNA in the annealing step of the PCR reaction, but in this state, the quencher substance is present on the probe, so fluorescence is not generated even when irradiated with excitation light. Suppressed.
- the fluorescent substance is released from the probe and inhibited by the quencher substance. is released and emits fluorescence.
- the amount of amplified product can be monitored by detecting the fluorescence.
- Conditions for PCR are not particularly limited, and optimum conditions may be determined for each PCR. Examples include the following conditions. 1) Thermal denaturation of double-stranded DNA to single-stranded DNA: The temperature is preferably 94-99°C and the time is 10-60 seconds. 2) Annealing: The temperature is generally 50°C or higher, preferably 52°C or higher, more preferably 55°C or higher, and generally 65°C or lower, preferably 63°C or lower, more preferably 60°C or lower. Also, it is usually 50 to 65°C, preferably 52 to 63°C, more preferably 55 to 60°C. The time is usually 5 seconds or more, preferably 10 seconds or more, and usually 2 minutes or less, preferably 1 minute or less.
- DNA elongation reaction The temperature is generally 65°C or higher, preferably 68°C or higher, and generally 74°C or lower, preferably 72°C or lower. Also, it is usually about 65 to 74°C, preferably 68 to 72°C.
- the time is usually 5 seconds or more, preferably 10 seconds or more, and usually 2 minutes or less, preferably 1 minute or less. Also, it is usually 5 seconds to 2 minutes, preferably 10 seconds to 1 minute.
- the annealing and the DNA elongation reaction can be performed simultaneously without being separated.
- Reverse transcription and PCR at the above temperature and time can be performed using a thermal cycler generally used for PCR or a device dedicated to real-time PCR in which a thermal cycler and a spectrofluorometer are integrated.
- the chain length of the PCR amplification product can be appropriately selected in consideration of factors such as shortening of the PCR amplification time.
- the chain length of the PCR amplification product is preferably 1000 bp or less, more preferably 700 bp or less, and even more preferably 500 bp or less.
- the chain length of the PCR amplification product has a lower limit of 30 to 40 bp, which is the chain length of the PCR amplification product when using a primer of around 15 bases that can avoid non-specific hybridization in PCR, and is preferably 50 bp or more. 100 bp or more is more preferable.
- the chain length of the PCR amplification product is preferably 30 to 1000 bp, more preferably 50 to 700 bp, even more preferably 100 to 500 bp.
- Probes or primers used for the above measurements i.e., target genes, internal standard genes, or primers for specifically recognizing and amplifying nucleic acids derived from them, or target genes, internal standard genes, or derived from them
- Probes for specifically detecting a nucleic acid that is a target gene or an internal standard gene can be designed based on the nucleotide sequence that constitutes the target gene or internal standard gene.
- “specifically recognize” means that, for example, in the RT-PCR method, the detected product or product is the gene or It means that it can be determined that it is a nucleic acid derived from it.
- an oligonucleotide comprising a certain number of nucleotides complementary to a DNA consisting of a nucleotide sequence that constitutes the target gene or internal standard gene of the present invention or its complementary strand can be used.
- complementary strand refers to one strand of a double-stranded DNA consisting of base pairs of A:T (U in the case of RNA) and G:C against the other strand.
- nucleotide sequence identity is not limited to the case of a completely complementary sequence in the certain number of contiguous nucleotide regions, preferably 80% or more, more preferably 90% or more, still more preferably 95% or more, and further More preferably, they should have 98% or more of nucleotide sequence identity.
- the identity of nucleotide sequences can be determined by algorithms such as BLAST. When such oligonucleotides are used as primers, they only need to be capable of specific annealing and chain extension. Those having a chain length of preferably 50 bases or less, more preferably 35 bases or less are included. In addition, when used as a probe, it is sufficient that specific hybridization can be achieved.
- oligonucleotide can be DNA or RNA, and may be synthetic or natural. Also, the probes used for hybridization are usually labeled ones.
- nested PCR can increase the yield and specificity of the amplified product.
- the first round of PCR is performed using the first primer pair, the target sequence is amplified, and then the amplified product is used as a template, and the second primer designed inside the amplified region by the first primer pair.
- a second round of PCR can be performed using the pair to obtain an amplified product. From the viewpoint of quantification, at least the second round of PCR among the two rounds of PCR is preferably real-time PCR or multiplex real-time PCR.
- the target gene and the internal standard gene are amplified based on the RNA extracted from the SSL sample, and the expression level of the target gene is calculated based on the amplified product.
- the expression level of the target gene can be calculated according to a relative quantification method commonly used in the art.
- the relative quantification method for example, the amplified product of the target gene and the amplified product of the internal standard gene are subjected to electrophoresis, and the densities of the bands on the gel are compared to determine the relative expression level of the target gene with respect to the internal standard gene.
- Methods of calculation and methods of relative quantification in real-time PCR include known calibration curve method, - ⁇ Ct method, ⁇ Ct method (comparative Ct method), and the like. Of the relative quantification methods, the ⁇ Ct method or the ⁇ Ct method is preferred because it does not require a calibration curve.
- relative quantification may be performed as follows, for example.
- a dilution series of a standard sample is prepared, and using this as a template, the target gene and internal standard gene are each amplified by PCR to determine the Ct value.
- the Ct value means the number of cycles (threshold cycle) when the amount of amplified product of PCR reaches a certain amount.
- the amplified product theoretically doubles with each cycle, so when the concentration of the standard sample and the determined Ct value are plotted, the relationship between the two is represented by a straight line, which can be used as a calibration curve. can be done.
- the sample is also subjected to PCR under the same conditions to determine the Ct value, and from this value and the standard curve, the quantitative results of the target gene and internal standard gene in the sample are obtained. Furthermore, by dividing the quantification result of the target gene by the quantification result of the internal standard gene, the expression level of the target gene is corrected by the expression level of the internal standard gene, and the expression level of the target gene is calculated.
- the expression level of the target gene may be expressed as a relative amount when the result of a certain sample is set to 1 so that the difference in the expression level between samples can be easily grasped.
- relative quantification may be performed as follows, for example. First, each of the target gene and the internal standard gene in sample A is amplified by PCR, the Ct value is obtained, and the difference ( ⁇ Ct) between the Ct value of the target gene and the Ct value of the internal standard gene is calculated.
- ⁇ Ct is a value obtained by correcting the quantification result of the target gene with the quantification result of the internal standard gene.
- PCR is performed under the same conditions for specimen B as a comparison target, and the Ct value and ⁇ Ct are obtained.
- the obtained ⁇ Ct is substituted into the formula (2 ⁇ Ct ), and the expression levels between specimens A and B are compared based on the calculated relative expression levels.
- relative quantification may be performed as follows. First, each of the target gene and the internal standard gene in sample A is amplified by PCR, the Ct value is obtained, and the difference ( ⁇ Ct) between the Ct value of the target gene and the Ct value of the internal standard gene is calculated.
- ⁇ Ct is a value obtained by correcting the quantification result of the target gene with the quantification result of the internal standard gene.
- PCR is performed under the same conditions for specimen B as a comparison target, and the Ct value and ⁇ Ct are determined.
- the difference ( ⁇ Ct) between ⁇ Ct of specimen A and ⁇ Ct of specimen B is obtained.
- ⁇ Ct is a value that reflects the difference in the expression level of the target gene between samples. Furthermore, the obtained ⁇ Ct is substituted into the equation (2 ⁇ Ct ). The value obtained here indicates how many times higher or lower the expression level of the target gene in sample A is than the expression level of the target gene in sample B. That is, the expression level of the target gene in sample A is expressed as a relative amount when the expression level in sample B is set to 1.
- the kit for measuring the expression level of the target gene contained in the skin surface lipid sample used in the method of the present invention includes a test reagent for measuring the expression level of the internal standard gene of the present invention in SSL collected from a subject. It contains Specifically, a reagent for nucleic acid amplification and hybridization, containing an oligonucleotide (for example, a primer or probe for PCR) that specifically binds (hybridizes) to the internal standard gene of the present invention or a nucleic acid derived therefrom. etc. Oligonucleotides included in the kit can be obtained by known methods as described above.
- the kit contains standard samples for standard curve creation, RT reagents, PCR reagents, labeling reagents, buffers, instruments and controls necessary for testing, and tools for collecting SSL (e.g., oil-removing film for collecting SSL), a reagent for storing the collected SSL, a storage container, a reagent for extracting and purifying RNA from the collected SSL, and the like.
- SSL standard curve creation
- RT reagents e.g., PCR reagents, labeling reagents, buffers, instruments and controls necessary for testing, and tools for collecting SSL (e.g., oil-removing film for collecting SSL), a reagent for storing the collected SSL, a storage container, a reagent for extracting and purifying RNA from the collected SSL, and the like.
- the expression level of the target gene contained in the skin surface lipid sample including using at least one gene selected from the group consisting of the genes shown in Tables 5 to 7 below as an internal standard gene in PCR how to measure.
- ⁇ 2> The method of ⁇ 1>, further comprising correcting the amount of the amplified product of the target gene with the amount of the amplified product of the internal standard gene, and calculating the expression level of the target gene.
- ⁇ 3> amplifying the target gene; The method of ⁇ 1>, further comprising amplifying an internal standard gene; and correcting the amount of the amplified product of the target gene with the amount of the amplified product of the internal standard gene, and calculating the expression level of the target gene.
- RNA from a skin surface lipid sample collected from a subject Amplifying a gene of interest based on the extracted RNA; Amplifying an internal standard gene based on the extracted RNA; and Correcting the amount of the amplified product of the target gene with the amount of the amplified product of the internal standard gene, and calculating the expression level of the target gene. , the method of ⁇ 1>.
- RNA from a skin surface lipid specimen collected from a subject Synthesizing cDNA using the extracted RNA as a template; Amplifying the target gene using the resulting cDNA as a template; Amplifying the internal standard gene using the obtained cDNA as a template; and Correcting the amount of the amplified product of the target gene with the amount of the amplified product of the internal standard gene, and calculating the expression level of the target gene,
- ⁇ 6> The method according to any one of ⁇ 1> to ⁇ 5>, wherein the internal standard gene is at least one gene selected from the group consisting of the genes shown in Tables 5 and 6 above.
- ⁇ 7> The method according to any one of ⁇ 1> to ⁇ 6>, wherein the internal standard gene is at least one gene selected from the group consisting of the genes shown in Table 5 above.
- the internal standard gene is preferably at least one selected from the group consisting of FAU, ARF1, RPS8, RPL30, UBA52, RPL10A, RAB7A, PSMB3, RPL36, EIF1, RAC1, RPL29, CSNK2B, RPS15A, and BZW1 more preferably at least one gene selected from the group consisting of FAU, ARF1, RPS8, RPL30, UBA52, RPL10A, RAB7A, and PSMB3, more preferably from the group consisting of FAU, ARF1, RPS8, and RPL30
- at least one gene is selected, more preferably at least one gene selected from the group consisting of FAU and ARF1.
- the internal standard gene is UBA52, PSMB3, RPL36, EIF1, RPS15A, BZW1, OAZ1, ATP5B, BRK1, EEF1G, PCBP2, RPL12, IER5, ARL8B, PCBP1, RPL4, TMEM66, SUMO2, RPS23, NOTCH2NL, RPL36A,
- the internal standard gene is UBA52, PSMB3, RPL36, EIF1, RPS15A, BZW1, OAZ1, ATP5B, BRK1, EEF1G, PCBP2, RPL12, IER5, ARL8B, PCBP1, RPL4, TMEM66, SUMO2, RPS23, NOTCH2NL, RPL36A, The method of any one of ⁇ 1> to ⁇ 5> and ⁇ 9>, wherein the gene is at least one gene selected from the group consisting of CHMP1B, MYL12A, RPL18A, DDX6, and YWHAE.
- the internal standard gene is at least one gene selected from the group consisting of UBA52, PSMB3, RPL36, EIF1, RPS15A, BZW1, OAZ1, ATP5B, BRK1, EEF1G, PCBP2, RPL12, and IER5, ⁇ 1> to ⁇ 5>, ⁇ 9> and ⁇ 10>.
- ⁇ 12> The method according to any one of ⁇ 1> to ⁇ 11>, wherein the target gene and the internal standard gene are amplified by qPCR, preferably by multiplex qPCR.
- ⁇ 13> For measuring the expression level of a target gene contained in a lipid sample on the skin surface used in any of the methods ⁇ 1> to ⁇ 12>, containing an oligonucleotide that specifically hybridizes with the internal gene kit.
- ⁇ 14> At least one gene selected from the group consisting of the genes shown in Tables 5 to 7 above, as an internal standard gene in measurement of the expression level of the target gene contained in the lipid sample on the skin surface using PCR Use of.
- the measurement of the expression level of the target gene further comprises correcting the amount of the amplification product of the target gene with the amount of the amplification product of the internal standard gene to calculate the expression level of the target gene, ⁇ 14> Use of.
- ⁇ 14> measurement of the expression level of the target gene, extracting RNA from a superficial skin lipid specimen obtained from a subject; Synthesizing cDNA using the extracted RNA as a template; Amplifying the target gene using the resulting cDNA as a template; Amplifying the internal standard gene using the obtained cDNA as a template; and Correcting the amount of the amplified product of the target gene with the amount of the amplified product of the internal standard gene, and calculating the expression level of the target gene, Use of ⁇ 14>. ⁇ 19> The use of any one of ⁇ 14> to ⁇ 18>, wherein the internal standard gene is at least one gene selected from the group consisting of the genes shown in Tables 5 and 6 above.
- ⁇ 20> The use of any one of ⁇ 14> to ⁇ 19>, wherein the internal standard gene is at least one gene selected from the group consisting of the genes shown in Table 5 above.
- the internal standard gene is preferably at least one selected from the group consisting of FAU, ARF1, RPS8, RPL30, UBA52, RPL10A, RAB7A, PSMB3, RPL36, EIF1, RAC1, RPL29, CSNK2B, RPS15A, and BZW1 more preferably at least one gene selected from the group consisting of FAU, ARF1, RPS8, RPL30, UBA52, RPL10A, RAB7A, and PSMB3, more preferably from the group consisting of FAU, ARF1, RPS8, and RPL30
- at least one gene is selected, more preferably at least one gene selected from the group consisting of FAU and ARF1.
- ⁇ 22> the internal standard gene is UBA52, PSMB3, RPL36, EIF1, RPS15A, BZW1, OAZ1, ATP5B, BRK1, EEF1G, PCBP2, RPL12, IER5, ARL8B, PCBP1, RPL4, TMEM66, SUMO2, RPS23, NOTCH2NL, RPL36A, Use of any one of ⁇ 14> to ⁇ 18>, which is at least one gene selected from the group consisting of CHMP1B, MYL12A, RPL18A, DDX6, YWHAE, SUPT4H1, PPP4C, and RPL27A.
- ⁇ 23> the internal standard gene is UBA52, PSMB3, RPL36, EIF1, RPS15A, BZW1, OAZ1, ATP5B, BRK1, EEF1G, PCBP2, RPL12, IER5, ARL8B, PCBP1, RPL4, TMEM66, SUMO2, RPS23, NOTCH2NL, RPL36A, Use of any one of ⁇ 14> to ⁇ 18> and ⁇ 22>, which is at least one gene selected from the group consisting of CHMP1B, MYL12A, RPL18A, DDX6, and YWHAE.
- the internal standard gene is at least one gene selected from the group consisting of UBA52, PSMB3, RPL36, EIF1, RPS15A, BZW1, OAZ1, ATP5B, BRK1, EEF1G, PCBP2, RPL12, and IER5, ⁇ Use of any one of 14> to ⁇ 18>, ⁇ 22> and ⁇ 23>.
- ⁇ 25> The use of any one of ⁇ 14> to ⁇ 24>, wherein the target gene and the internal standard gene are amplified by qPCR, preferably by multiplex qPCR.
- Example 1 Collection of SSL, RNA Extraction, and Comprehensive Gene Expression Analysis 1) Subjects A total of 1953 subjects, 803 healthy men (20s to 80s) and 1150 healthy women (20s to 80s), were used as subjects. . 2) Collection of SSL Superficial skin lipids (SSL) were collected from the entire face of the subject using an oil blotting film (5.0 cm ⁇ 8.0 cm, 3M Company). The collector's lab gloves were changed between subjects to prevent cross-contamination of sebum.
- SSL Superficial skin lipids
- the oil-blotting film from which the sebum was collected was immediately placed in an RNase-free (dry-heat-treated) 20 mL glass vial bottle containing 1 g of molecular sieves or a 5 mL tube (Eppendorf DNA LoBind 5 mL, PCR clean) containing 1 g of molecular sieves, Placed on dry ice and then stored at -80°C. 3) RNA Extraction and Sequencing The blotting film from which the sebum was collected in 2) above was cut into appropriate sizes, and RNA was extracted using QIAzol Lysis Reagent (Qiagen) according to the attached protocol. Based on the extracted RNA, reverse transcription was performed at 42° C.
- the resulting PCR product was purified with Ampure XP (Beckman Coulter, Inc.) and then subjected to buffer reconstitution, primer sequence digestion, adapter ligation and purification, and amplification to prepare a library.
- the prepared library was loaded into the Ion 540 Chip and sequenced using the Ion S5/XL system (Life Technologies Japan). Genes from which each read sequence was derived were determined by genetic mapping each read sequence obtained by sequencing against hg19 AmpliSeq Transcriptome ERCC v1, which is a reference sequence of the human genome.
- Example 2 Identification of internal standard genes Based on the data obtained in Example 1, a male dataset, a female dataset, and a dataset combining males and females were created, and these three datasets were targeted. As such, the following analysis was performed. Genes with a gene detection rate of 80% or more (Log2 RPM method) or 90% or more (RLE method) were selected for each of the three datasets (male dataset/female dataset/male and female dataset). It was analyzed (Gene Threshold) and normalized by two methods, Log2 RPM method and RLE method. The RLE method calculates a coefficient called Size factor and uses this coefficient to normalize the read count data of each sample. The Log2 RPM method sets the expression level of each gene to 1 million.
- Log2 RPM method sets the expression level of each gene to 1 million.
- CV Z-Score ⁇ -1 corresponded to the top 15.87% of the analyzed genes with small expression fluctuations.
- the CV Z-Score of RPLP0 which is considered suitable as an internal standard gene in gene expression analysis of epidermal keratinocytes, was -1.111. Note that these CV Z-Scores are averages of 6 CV Z-Scores obtained from 3 data sets and 2 normalization techniques.
- genes with a CV Z-Score ⁇ -1 with high expression stability genes with a CV Z-Score equal to or smaller than RPLP0 and more stably expressed in SSL are further selected.
- a total of 52 genes were identified.
- 29 genes were included in all three datasets (Table 8), and 19 genes were included in any two datasets.
- species (12 species common to the male dataset and the male and female datasets shown in Table 9-1, and 7 species common to the female dataset and the male and female datasets shown in Table 9-2);
- the CV Z-scores shown in Tables 8, 9-1, and 9-2 are the average values of the CV Z-scores based on two normalization methods in each data set for which commonality was confirmed.
- the CV Z-scores shown in Tables 10-1 and 10-2 are the CV Z-scores based on the two normalization techniques on the relevant datasets. In each table, those reported as housekeeping genes are marked with * (see Genome Analysis, 2003, 19(7):362-365). These 52 genes were found to be more stably expressed in SSL-derived RNA, and were shown to be usable as internal standard genes when gene expression was analyzed using SSL as a sample to be analyzed.
- Example 3 Confirmation of Correlation Between Real-Time PCR Data and NGS Data Sebum was collected from 22 healthy women, and RNA was extracted and purified.
- a library containing DNA derived from the 20802 gene was prepared from the resulting reverse transcription reaction product by multiplex PCR (1st round PCR, Ion AmpliSeq Transcriptome Human Gene Expression Kit). The resulting 1st round PCR product was purified using Ampure XP. The resulting purified product was divided into next-generation sequencer analysis and real-time PCR measurement. One purified product was subjected to buffer reconstitution, primer sequence digestion, adapter ligation and purification, amplification, and comprehensive gene expression information was obtained by next-generation sequencer analysis and used as NGS data.
- the other divided 1-st round PCR-purified product was used as a template for real-time PCR measurement, and real-time PCR was performed using primers (nested primers) designed inside the 1-st round PCR amplification region.
- primers nested primers
- the Ct values of 19 genes selected as target genes and 3 genes (RPLP0, FAU, ARF1) as internal control genes were obtained.
- the difference in Ct value was calculated and used as qPCR data.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
一方、特許文献1には、皮膚表上脂質(skin surface lipids;SSL)に被験体の皮膚細胞に由来するRNAが含まれていること、SSLに含まれるRNAが生体の遺伝子発現解析用の試料として有用であること、SSLから表皮、汗腺、毛包及び皮脂腺のマーカー遺伝子が検出できることが記載されている。しかし、SSLを用いた遺伝子発現解析における適切な内部標準遺伝子については明らかになっていない。
(非特許文献1)Journal of Investigative Dermatology, 2009, 129(3):535-537
(非特許文献2)Acta Biochem Biophys Sin, 2014, 46(4):330-337
(非特許文献3)Journal of Investigative Dermatology, 2009, 129(3):770-773
(1)PCRにおいて下記表1に示される遺伝子からなる群より選択される少なくとも1種の遺伝子を内部標準遺伝子として用いることを含む、SSL検体に含まれる目的遺伝子の発現量を測定する方法。
(2)前記内部標準遺伝子と特異的にハイブリダイズするオリゴヌクレオチドを含有する、(1)の方法に用いられるSSL検体に含まれる目的遺伝子の発現量の測定用キット。
(3)下記表1に示される遺伝子からなる群より選択される少なくとも1種の遺伝子の、PCRを用いたSSL検体に含まれる目的遺伝子の発現量の測定における内部標準遺伝子としての使用。
また、当該「遺伝子」は特定の塩基配列で表される「遺伝子」だけではなく、これらの同族体(すなわち、ホモログもしくはオーソログ)、遺伝子多型等の変異体、及び誘導体をコードする核酸が包含される。
本明細書中に開示される遺伝子の名称(Gene Symbol)及びGene IDは、NCBI([www.ncbi.nlm.nih.gov/])に記載のあるOfficial Symbol及びGene IDに従う。
また、本明細書において、「ハウスキーピング遺伝子」とは、細胞の維持や増殖に不可欠な遺伝子であって、多くの組織や細胞に共通して一定量発現する遺伝子のことを意味する。一般的なハウスキーピング遺伝子としては、例えば、GAPDH、ACTB等が知られている(Genome Analysis, 2003, 19(7):362-365参照)。
したがって、斯かる52遺伝子からなる群より選択される遺伝子は、SSLに含まれる目的遺伝子の発現量を測定する際の、qPCRにおける内部標準遺伝子(以下、本発明の内部標準遺伝子ともいう)として使用できる。内部標準遺伝子としては、いずれか1遺伝子を単独で用いてもよいし、2以上の遺伝子を組み合わせて用いてもよい。
本発明の内部標準遺伝子は、好ましくは表2及び3に示される遺伝子からなる群より選択される少なくとも1種の遺伝子であり、より好ましくは表2に示される遺伝子からなる群より選択される少なくとも1種の遺伝子であり、さらに好ましくはFAU、ARF1、RPS8、RPL30、UBA52、RPL10A、RAB7A、PSMB3、RPL36、EIF1、RAC1、RPL29、CSNK2B、RPS15A、及びBZW1の15遺伝子からなる群より選択される少なくとも1種の遺伝子であり、さらに好ましくはFAU、ARF1、RPS8、RPL30、UBA52、RPL10A、RAB7A、及びPSMB3の8遺伝子からなる群より選択される少なくとも1種の遺伝子であり、さらに好ましくはFAU、ARF1、RPS8、及びRPL30の4遺伝子からなる群より選択される少なくとも1種の遺伝子であり、さらに好ましくはFAU及びARF1の2遺伝子から選択される少なくとも1種の遺伝子である。
SSLからのRNAの抽出には、生体試料からのRNAの抽出又は精製に通常使用される方法、例えば、フェノール/クロロホルム法、AGPC(acid guanidinium thiocyanate-phenol-chloroform extraction)法、又はTRIzol(登録商標)、RNeasy(登録商標)、QIAzol(登録商標)等のカラムを用いた方法、シリカをコーティングした特殊な磁性体粒子を用いる方法、Solid Phase Reversible Immobilization磁性体粒子を用いる方法、ISOGEN等の市販のRNA抽出試薬による抽出等を用いることができる。
該逆転写における伸長反応は、温度を好ましくは42℃±1℃、より好ましくは42℃±0.5℃、さらに好ましくは42℃±0.25℃に調整し、一方、反応時間を好ましくは60分間以上、より好ましくは80~120分間に調整するのが好ましい。
ここで、逆転写によるcDNA合成(RT)及びPCRは、1ステップで行ってもよく、2ステップで行ってもよく、目的に応じていずれかを適宜選択すればよい。1ステップRT-PCRは、単一チューブ内でRT及びPCRの一連の反応を連続的に行うもので、簡便性に優れ、RTとPCRの操作間のコンタミネーションを防止することができる。一方、2ステップRT-PCRでは、RTにランダムプライマーを使用することができるため、単一のRNA検体から複数の目的遺伝子の発現量を測定することができる。RT-PCRにおけるPCRとしては、上記のPCRと同様のものが挙げられる。
増幅産物の検出には、増幅産物を特異的に認識することができる公知の手段を用いることができる。例えば、予めRI、蛍光物質等で標識しておいたプライマーを用いてPCRを行うことによって産生される標識二本鎖DNAを検出する方法等を用いることができる。
1)2本鎖DNAの1本鎖DNAへの熱変性:温度は好ましくは94~99℃で、時間は10~60秒間である。
2)アニーリング:温度は、通常50℃以上、好ましくは52℃以上、より好ましくは55℃以上であり、通常65℃以下、好ましくは63℃以下、より好ましくは60℃以下である。また、通常50~65℃、好ましくは52~63℃、より好ましくは55~60℃である。時間は、通常5秒以上、好ましくは10秒以上であり、通常2分以下、好ましくは1分以下である。また、通常5秒~2分、好ましくは10秒~1分である。
3)DNA伸長反応:温度は、通常65℃以上、好ましくは68℃以上であり、通常74℃以下、好ましくは72℃以下である。また、通常65~74℃程度、好ましくは68~72℃である。時間は、通常5秒以上、好ましくは10秒以上であり、通常2分以下、好ましくは1分以下である。また、通常5秒~2分、好ましくは10秒~1分である。
ここで、アニーリングとDNA伸長反応は分けずに同時に行うことも可能である。
上記1)~3)の反応を1サイクルとして、これを通常30サイクル以上、好ましくは35サイクル以上、また、通常50サイクル以下、好ましくは45サイクル以下で行えばよい。
上記のような温度及び時間での逆転写及びPCRは、一般的にPCRに使用されるサーマルサイクラー又はサーマルサイクラーと分光蛍光光度計を一体化したリアルタイムPCR専用の装置を用いて行うことができる。
具体的には、本発明の目的遺伝子又は内部標準遺伝子を構成する塩基配列からなるDNA又はその相補鎖に相補的な一定数のヌクレオチドを含むオリゴヌクレオチドを利用することができる。ここで「相補鎖」とは、A:T(RNAの場合はU)、G:Cの塩基対からなる2本鎖DNAの一方の鎖に対する他方の鎖を指す。また、「相補的」とは、当該一定数の連続したヌクレオチド領域で完全に相補配列である場合に限られず、好ましくは80%以上、より好ましくは90%以上、さらに好ましくは95%以上、さらにより好ましく98%以上の塩基配列上の同一性を有すればよい。塩基配列の同一性は、前記BLAST等のアルゴリズムにより決定することができる。
斯かるオリゴヌクレオチドは、プライマーとして用いる場合には、特異的なアニーリング及び鎖伸長ができればよく、通常、例えば10塩基以上、好ましくは15塩基以上、より好ましくは20塩基以上、かつ例えば100塩基以下、好ましくは50塩基以下、より好ましくは35塩基以下の鎖長を有するものが挙げられる。また、プローブとして用いる場合には、特異的なハイブリダイゼーションができればよく、本発明の目的遺伝子又は内部標準遺伝子を構成する塩基配列からなるDNA(又はその相補鎖)の少なくとも一部若しくは全部の配列を有し、例えば10塩基以上、好ましくは15塩基以上、かつ例えば100塩基以下、好ましくは50塩基以下、より好ましくは25塩基以下の鎖長のものが用いられる。
なお、ここで、「オリゴヌクレオチド」は、DNAあるいはRNAであることができ、合成されたものでも天然のものでもよい。また、ハイブリダイゼーションに用いるプローブは、通常標識したものが用いられる。
また、当該キットには、上記核酸の他、検量線作成用標準サンプル、RT試薬、PCR試薬、標識試薬、緩衝液や、試験に必要な器具やコントロール、SSLを採取するための用具(例えば、SSLを採取するための脂取りフィルムなど)、採取したSSLを保存するための試薬、保存用の容器、採取したSSLからRNAを抽出・精製するための試薬等を含むことができる。
<1>PCRにおいて下記表5~7に示される遺伝子からなる群より選択される少なくとも1種の遺伝子を内部標準遺伝子として用いることを含む、皮膚表上脂質検体に含まれる目的遺伝子の発現量を測定する方法。
<3>目的遺伝子を増幅すること;
内部標準遺伝子を増幅すること;及び
目的遺伝子の増幅産物の量を内部標準遺伝子の増幅産物の量で補正し、目的遺伝子の発現量を算出すること、をさらに含む、<1>の方法。
<4>被験体から採取した皮膚表上脂質検体からRNAを抽出すること;
抽出されたRNAを基にして目的遺伝子を増幅すること;
抽出されたRNAを基にして内部標準遺伝子を増幅すること;及び
目的遺伝子の増幅産物の量を内部標準遺伝子の増幅産物の量で補正し、目的遺伝子の発現量を算出すること、をさらに含む、<1>の方法。
<5>被験体から採取した皮膚表上脂質検体からRNAを抽出すること;
抽出されたRNAを鋳型としてcDNAを合成すること;
得られたcDNAを鋳型として目的遺伝子を増幅すること;
得られたcDNAを鋳型として内部標準遺伝子を増幅すること;及び
目的遺伝子の増幅産物の量を内部標準遺伝子の増幅産物の量で補正し、目的遺伝子の発現量を算出すること、をさらに含む、<1>の方法。
<6>前記内部標準遺伝子が前記表5及び6に示される遺伝子からなる群より選択される少なくとも1種の遺伝子である、<1>~<5>のいずれかの方法。
<7>前記内部標準遺伝子が前記表5に示される遺伝子からなる群より選択される少なくとも1種の遺伝子である、<1>~<6>のいずれかの方法。
<8>前記内部標準遺伝子が好ましくはFAU、ARF1、RPS8、RPL30、UBA52、RPL10A、RAB7A、PSMB3、RPL36、EIF1、RAC1、RPL29、CSNK2B、RPS15A、及びBZW1からなる群より選択される少なくとも1種の遺伝子、より好ましくはFAU、ARF1、RPS8、RPL30、UBA52、RPL10A、RAB7A、及びPSMB3からなる群より選択される少なくとも1種の遺伝子、さらに好ましくはFAU、ARF1、RPS8、及びRPL30からなる群より選択される少なくとも1種の遺伝子、さらに好ましくはFAU及びARF1からなる群より選択される少なくとも1種の遺伝子である、<1>~<7>のいずれかの方法。
<9>前記内部標準遺伝子がUBA52、PSMB3、RPL36、EIF1、RPS15A、BZW1、OAZ1、ATP5B、BRK1、EEF1G、PCBP2、RPL12、IER5、ARL8B、PCBP1、RPL4、TMEM66、SUMO2、RPS23、NOTCH2NL、RPL36A、CHMP1B、MYL12A、RPL18A、DDX6、YWHAE、SUPT4H1、PPP4C、及びRPL27Aからなる群より選択される少なくとも1種の遺伝子である、<1>~<5>のいずれかの方法。
<10>前記内部標準遺伝子がUBA52、PSMB3、RPL36、EIF1、RPS15A、BZW1、OAZ1、ATP5B、BRK1、EEF1G、PCBP2、RPL12、IER5、ARL8B、PCBP1、RPL4、TMEM66、SUMO2、RPS23、NOTCH2NL、RPL36A、CHMP1B、MYL12A、RPL18A、DDX6、及びYWHAEからなる群より選択される少なくとも1種の遺伝子である、<1>~<5>及び<9>のいずれかの方法。
<11>前記内部標準遺伝子がUBA52、PSMB3、RPL36、EIF1、RPS15A、BZW1、OAZ1、ATP5B、BRK1、EEF1G、PCBP2、RPL12、及びIER5からなる群より選択される少なくとも1種の遺伝子である、<1>~<5>、<9>及び<10>のいずれかの方法。
<12>前記目的遺伝子及び前記内部標準遺伝子をqPCRにより、好ましくはマルチプレックスqPCRにより増幅するものである、<1>~<11>のいずれかの方法。
<13>前記内部遺伝子と特異的にハイブリダイズするオリゴヌクレオチドを含有する、<1>~<12>のいずれかの方法に用いられる皮膚表上脂質検体に含まれる目的遺伝子の発現量の測定用キット。
<15>前記目的遺伝子の発現量の測定が、目的遺伝子の増幅産物の量を内部標準遺伝子の増幅産物の量で補正し、目的遺伝子の発現量を算出すること、をさらに含む、<14>の使用。
<16>前記目的遺伝子の発現量の測定が、
目的遺伝子を増幅すること;
内部標準遺伝子を増幅すること;及び
目的遺伝子の増幅産物の量を内部標準遺伝子の増幅産物の量で補正し、目的遺伝子の発現量を算出すること、をさらに含む、<14>の使用。
<17>前記目的遺伝子の発現量の測定が、
被験体から採取した皮膚表上脂質検体からRNAを抽出すること;
抽出されたRNAを基にして目的遺伝子を増幅すること;
抽出されたRNAを基にして内部標準遺伝子を増幅すること;及び
目的遺伝子の増幅産物の量を内部標準遺伝子の増幅産物の量で補正し、目的遺伝子の発現量を算出すること、をさらに含む、<14>の使用。
<18>前記目的遺伝子の発現量の測定が、
被験体から採取した皮膚表上脂質検体からRNAを抽出すること;
抽出されたRNAを鋳型としてcDNAを合成すること;
得られたcDNAを鋳型として目的遺伝子を増幅すること;
得られたcDNAを鋳型として内部標準遺伝子を増幅すること;及び
目的遺伝子の増幅産物の量を内部標準遺伝子の増幅産物の量で補正し、目的遺伝子の発現量を算出すること、をさらに含む、<14>の使用。
<19>前記内部標準遺伝子が前記表5及び6に示される遺伝子からなる群より選択される少なくとも1種の遺伝子である、<14>~<18>のいずれかの使用。
<20>前記内部標準遺伝子が前記表5に示される遺伝子からなる群より選択される少なくとも1種の遺伝子である、<14>~<19>のいずれかの使用。
<21>前記内部標準遺伝子が好ましくはFAU、ARF1、RPS8、RPL30、UBA52、RPL10A、RAB7A、PSMB3、RPL36、EIF1、RAC1、RPL29、CSNK2B、RPS15A、及びBZW1からなる群より選択される少なくとも1種の遺伝子、より好ましくはFAU、ARF1、RPS8、RPL30、UBA52、RPL10A、RAB7A、及びPSMB3からなる群より選択される少なくとも1種の遺伝子、さらに好ましくはFAU、ARF1、RPS8、及びRPL30からなる群より選択される少なくとも1種の遺伝子、さらに好ましくはFAU及びARF1からなる群より選択される少なくとも1種の遺伝子である、<14>~<20>のいずれかの使用。
<22>前記内部標準遺伝子がUBA52、PSMB3、RPL36、EIF1、RPS15A、BZW1、OAZ1、ATP5B、BRK1、EEF1G、PCBP2、RPL12、IER5、ARL8B、PCBP1、RPL4、TMEM66、SUMO2、RPS23、NOTCH2NL、RPL36A、CHMP1B、MYL12A、RPL18A、DDX6、YWHAE、SUPT4H1、PPP4C、及びRPL27Aからなる群より選択される少なくとも1種の遺伝子である、<14>~<18>のいずれかの使用。
<23>前記内部標準遺伝子がUBA52、PSMB3、RPL36、EIF1、RPS15A、BZW1、OAZ1、ATP5B、BRK1、EEF1G、PCBP2、RPL12、IER5、ARL8B、PCBP1、RPL4、TMEM66、SUMO2、RPS23、NOTCH2NL、RPL36A、CHMP1B、MYL12A、RPL18A、DDX6、及びYWHAEからなる群より選択される少なくとも1種の遺伝子である、<14>~<18>及び<22>のいずれかの使用。
<24>前記内部標準遺伝子がUBA52、PSMB3、RPL36、EIF1、RPS15A、BZW1、OAZ1、ATP5B、BRK1、EEF1G、PCBP2、RPL12、及びIER5からなる群より選択される少なくとも1種の遺伝子である、<14>~<18>、<22>及び<23>のいずれかの使用。
<25>前記目的遺伝子及び前記内部標準遺伝子をqPCRにより、好ましくはマルチプレックスqPCRにより増幅するものである、<14>~<24>のいずれかの使用。
1)被験者
健常男性803名(20~80歳代)、健常女性1150名(20~80歳代)の計1953名を被験者とした。
2)SSLの採取
あぶらとりフィルム(5.0cm×8.0cm、3M社)を用いて、被検者の顔全体から皮膚表上脂質(SSL)を採取した。皮脂のクロスコンタミネーションを防ぐ為、被検者ごとに採取者のラボグローブは交換した。皮脂を採取したあぶらとりフィルムはただちに1gのモレキュラーシーブスを含むRNase-free(乾熱処理済み)の20mLガラスバイアル瓶、或いは1gのモレキュラーシーブスを含む5mLチューブ(Eppendorf DNA LoBind 5mL,PCR clean)に入れ、ドライアイス上に静置し、その後-80℃にて保管した。
3)RNA抽出及びシーケンシング
上記2)の皮脂を採取したあぶらとりフィルムを適当な大きさに切断し、QIAzol Lysis Reagent(Qiagen)を用いて、付属のプロトコルに準じてRNAを抽出した。抽出されたRNAを元に、SuperScript VILO cDNA Synthesis kit(ライフテクノロジーズジャパン株式会社)を用いて42℃、90分間逆転写を行いcDNAの合成を行った。逆転写反応のプライマーには、キットに付属しているランダムプライマーを使用した。
得られたcDNAから、マルチプレックスPCRにより20802遺伝子に由来するDNAを含むライブラリーを調製した。マルチプレックスPCRは、Ion AmpliSeqTranscriptome Human Gene Expression Kit(ライフテクノロジーズジャパン株式会社)を用いて、[99℃、2分→(99℃、15秒→62℃、16分)×20サイクル→4℃、Hold]の条件で行った。得られたPCR産物は、Ampure XP(ベックマン・コールター株式会社)で精製した後に、バッファーの再構成、プライマー配列の消化、アダプターライゲーションと精製、増幅を行い、ライブラリーを調製した。
調製したライブラリーをIon 540 Chipにローディングし、Ion S5/XLシステム(ライフテクノロジーズジャパン株式会社)を用いてシーケンシングした。シーケンシングで得られた各リード配列をヒトゲノムのリファレンス配列であるhg19 AmpliSeq Transcriptome ERCC v1に対して遺伝子マッピングすることで、各リード配列の由来する遺伝子を決定した。
実施例1で得られたデータを元に、男性のデータセット、女性のデータセット、男性及び女性を合わせたデータセットを作成し、これら3種のデータセットを対象として、以下の解析を行った。
3種のデータセット(男性のデータセット/女性のデータセット/男性及び女性のデータセット)ごとに、遺伝子検出率が80%以上(Log2 RPM法)あるは90%以上(RLE法)の遺伝子を解析対象とし(Gene Threshold)、Log2 RPM法及びRLE法の2手法にて正規化を行った。RLE法は、Size factorと呼ばれる係数を計算し、この係数を利用して各サンプルのリードカウントデータを正規化する手法で、Log2 RPM法は、各遺伝子の発現量を総リード数が1millionとした場合の補正値として算出して正規化する手法である。RLE法におけるSize factorはデータサイズに依存するため、統合データを利用して内部標準遺伝子を抽出する際、汎用性に欠ける遺伝子を選抜する可能性が危惧されたため、Log2 RPM法による正規化データも使用し、両補正値に共通して一定割合の安定発現を認める汎用性の遺伝子を選抜した。遺伝子の発現安定性は、CV Z-scoreを利用して評価した。3種いずれかのデータセットの両補正データの平均値において、CV Z-scoreが-1以下であるより発現安定性が高い遺伝子を抽出した結果、男性のデータセットでは58種、女性のデータセットでは46種、さらに男性及び女性のデータセットでは70種の遺伝子が抽出された。これらCV Z-Score≦-1を認める遺伝子は、解析対象遺伝子のうち発現変動の小さい上位15.87%に該当していた。一般的に内部標準遺伝子として使用されるGAPDH及びACTBのCV Z-Scoreは、GAPDH=-0.345、ACTB=-0.505であり、SSL由来のRNAを対象とする場合は、CV Z-Score≦-1の発現安定性が高い遺伝子には該当しないことが明らかとなった。一方、表皮角化細胞の遺伝子発現解析における内部標準遺伝子として好適とされるRPLP0のCV Z-Scoreは、-1.111であった。なお、これらのCV Z-Scoreは、3種のデータセットと2種の正規化手法から得られた6つのCV Z-Scoreの平均値である。
そこで発現安定性が高い前記のCV Z-Score≦-1の遺伝子のうち、RPLP0と比較して、CV Z-Scoreが同等かそれよりも小さく、SSLにおいてより安定発現している遺伝子をさらに選抜し、計52種の遺伝子を同定した。これら52遺伝子に関して、3種のデータセット間における共通性を確認した結果、3種全てのデータセットに含まれる遺伝子が29種(表8)、いずれか2種のデータセットに含まれる遺伝子が19種(表9-1に示す男性のデータセットと男性及び女性のデータセットに共通する12種、及び表9-2に示す女性のデータセットと男性及び女性のデータセットに共通する7種)、いずれか1種のデータセットに含まれる遺伝子が4種(表10-1に示す男性のデータセットにおける2種、表10-2に示す男性及び女性のデータセットにおける2種)であった。表8、9-1、9-2に示すCV Z-scoreは、共通性が確認された各データセットにおける2種の正規化手法に基づくCV Z-scoreの平均値である。表10-1、10-2に示すCV Z-scoreは、該当するデータセットにおける2種の正規化手法に基づくCV Z-scoreである。各表中、ハウスキーピング遺伝子として報告があるものに*印を付す(Genome Analysis, 2003, 19(7):362-365参照)。
該52種の遺伝子は、SSL由来のRNAにおいてより安定発現している遺伝子であり、SSLを解析対象試料としてその遺伝子発現を解析する場合において内部標準遺伝子として使用可能であることが示された。
22名の健常女性から皮脂を採取し、RNA抽出及び精製を行った。SSL-RNAとRT Mixとを混合し逆転写を行い、得られた逆転写反応物からマルチプレックスPCRにより20802遺伝子に由来するDNAを含むライブラリーを調製した(1st round PCR、Ion AmpliSeqTranscriptome Human Gene Expression Kit)。Ampure XPを利用し、得られた1st round PCR産物を精製した。得られた精製産物を次世代シーケンサー解析用とリアルタイムPCR測定用とに分割した。片方の精製産物は、バッファーの再構成、プライマー配列の消化、アダプターライゲーションと精製、増幅を行い、次世代シーケンサー解析により網羅的遺伝子発現情報を取得し、NGSデータとした。分割したもう一方の1st round PCR精製産物は、リアルタイムPCR測定のテンプレートとし、1st round PCR増幅領域の内側に設計したプライマー(nested primer)を用いて、Real-time PCRを行った。22サンプルそれぞれについて、目的遺伝子(target gene)として選定した19種の遺伝子及び内部標準遺伝子(control gene)として3種の遺伝子(RPLP0、FAU、ARF1)のCt値を取得した。3種の内部標準遺伝子それぞれにおいて、Ct値の差分(ΔCt値;ΔCt=Ct_target gene-Ct_control gene)を算出し、qPCRデータとした。19種の目的遺伝子に関して、RPLP0、FAU、あるいはARF1を内部標準遺伝子とした3パターンのqPCRデータ(以下、ΔRPLP0、ΔFAU及びΔARF1と記す)とNGSデータ(Log2RPM)間のデータ相関性を確認した結果、表11に示すように皮膚において内部標準遺伝子として一般的に利用されているRPLP0(CV Z-score=-1.111)を内部標準としたqPCRデータ(ΔRPLP0)と比較して、よりCV Z-scoreが小さくSSL内部標準遺伝子として適していると考えられたFAU(CV Z-score=-1.363)、ARF1(CV Z-score=-1.328)を内部標準遺伝子として用いたqPCRデータ(ΔFAU、ΔARF1)のほうが、PCR定量データ全体の相関性が向上することが確認された。
Claims (8)
- 目的遺伝子の増幅産物の量を内部標準遺伝子の増幅産物の量で補正し、目的遺伝子の発現量を算出することを含む、請求項1記載の方法。
- 前記内部標準遺伝子が前記表1に示される遺伝子からなる群より選択される少なくとも1種の遺伝子である、請求項1又は2記載の測定方法。
- 前記内部標準遺伝子がFAU、ARF1、RPS8、RPL30、UBA52、RPL10A、RAB7A、PSMB3、RPL36、EIF1、RAC1、RPL29、CSNK2B、RPS15A、及びBZW1からなる群より選択される少なくとも1種の遺伝子である、請求項1~3のいずれか1項記載の測定方法。
- 前記内部標準遺伝子がFAU及びARF1からなる群より選択される少なくとも1種の遺伝子である、請求項1~4のいずれか1項記載の測定方法。
- 前記内部標準遺伝子がUBA52、PSMB3、RPL36、EIF1、RPS15A、BZW1、OAZ1、ATP5B、BRK1、EEF1G、PCBP2、RPL12、IER5、ARL8B、PCBP1、RPL4、TMEM66、SUMO2、RPS23、NOTCH2NL、RPL36A、CHMP1B、MYL12A、RPL18A、DDX6、YWHAE、SUPT4H1、PPP4C、及びRPL27Aからなる群より選択される少なくとも1種の遺伝子である、請求項1又は2記載の測定方法。
- 前記内部標準遺伝子と特異的にハイブリダイズするオリゴヌクレオチドを含有する、請求項1~6のいずれか1項記載の方法に用いられる皮膚表上脂質検体に含まれる目的遺伝子の発現量の測定用キット。
- 前記表1~3に示される遺伝子からなる群より選択される少なくとも1種の遺伝子の、PCRを用いた皮膚表上脂質検体に含まれる目的遺伝子の発現量の測定における内部標準遺伝子としての使用。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020237041517A KR20240015645A (ko) | 2021-05-31 | 2022-05-31 | 피부 표상 지질 검체 내부 표준 유전자 |
CN202280039127.7A CN117413069A (zh) | 2021-05-31 | 2022-05-31 | 皮肤表面脂质检体内部标准基因 |
EP22816124.6A EP4350004A1 (en) | 2021-05-31 | 2022-05-31 | Internal reference gene in skin surface lipid specimen |
US18/565,383 US20240263225A1 (en) | 2021-05-31 | 2022-05-31 | Internal reference gene in skin surface lipid specimen |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021091505 | 2021-05-31 | ||
JP2021-091505 | 2021-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022255378A1 true WO2022255378A1 (ja) | 2022-12-08 |
Family
ID=84323455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/022187 WO2022255378A1 (ja) | 2021-05-31 | 2022-05-31 | 皮膚表上脂質検体内部標準遺伝子 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20240263225A1 (ja) |
EP (1) | EP4350004A1 (ja) |
JP (1) | JP2022184823A (ja) |
KR (1) | KR20240015645A (ja) |
CN (1) | CN117413069A (ja) |
WO (1) | WO2022255378A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024111617A1 (ja) * | 2022-11-24 | 2024-05-30 | 花王株式会社 | 皮膚表上脂質検体内部標準遺伝子 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010514441A (ja) * | 2006-12-27 | 2010-05-06 | エスエヌユー アールアンドディービー ファウンデーション | 内部標準遺伝子を発掘するための遺伝子発現データ処理、分析方法 |
WO2018008319A1 (ja) | 2016-07-08 | 2018-01-11 | 花王株式会社 | 核酸試料の調製方法 |
JP2020074769A (ja) * | 2018-11-01 | 2020-05-21 | 花王株式会社 | 被験体の皮膚細胞に由来する核酸の調製方法 |
-
2022
- 2022-05-31 EP EP22816124.6A patent/EP4350004A1/en active Pending
- 2022-05-31 US US18/565,383 patent/US20240263225A1/en active Pending
- 2022-05-31 JP JP2022088919A patent/JP2022184823A/ja active Pending
- 2022-05-31 KR KR1020237041517A patent/KR20240015645A/ko unknown
- 2022-05-31 CN CN202280039127.7A patent/CN117413069A/zh active Pending
- 2022-05-31 WO PCT/JP2022/022187 patent/WO2022255378A1/ja active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010514441A (ja) * | 2006-12-27 | 2010-05-06 | エスエヌユー アールアンドディービー ファウンデーション | 内部標準遺伝子を発掘するための遺伝子発現データ処理、分析方法 |
WO2018008319A1 (ja) | 2016-07-08 | 2018-01-11 | 花王株式会社 | 核酸試料の調製方法 |
JP2020074769A (ja) * | 2018-11-01 | 2020-05-21 | 花王株式会社 | 被験体の皮膚細胞に由来する核酸の調製方法 |
Non-Patent Citations (3)
Title |
---|
ACTA BIOCHEM BIOPHYS SIN, vol. 46, no. 4, 2014, pages 330 - 337 |
GENOME ANALYSIS, vol. 19, no. 7, 2003, pages 362 - 365 |
JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 129, no. 3, 2009, pages 770 - 773 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024111617A1 (ja) * | 2022-11-24 | 2024-05-30 | 花王株式会社 | 皮膚表上脂質検体内部標準遺伝子 |
Also Published As
Publication number | Publication date |
---|---|
EP4350004A1 (en) | 2024-04-10 |
KR20240015645A (ko) | 2024-02-05 |
US20240263225A1 (en) | 2024-08-08 |
JP2022184823A (ja) | 2022-12-13 |
CN117413069A (zh) | 2024-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Farrugia et al. | Efficiency evaluation of a DNA extraction and purification protocol on archival formalin-fixed and paraffin-embedded tissue | |
Benson et al. | An analysis of select pathogenic messages in lesional and non-lesional psoriatic skin using non-invasive tape harvesting | |
CN108474033B (zh) | 来源于体液的miRNA的品质的评价方法 | |
WO2012093821A2 (ko) | 초기유방암의 예후 예측용 유전자 및 이를 이용한 초기유방암의 예후예측 방법 | |
Zhao et al. | Identification of aged bloodstains through mRNA profiling: experiments results on selected markers of 30-and 50-year-old samples | |
WO2022255378A1 (ja) | 皮膚表上脂質検体内部標準遺伝子 | |
CN112513267B (zh) | 体液样本的品质评价方法 | |
CN110592220B (zh) | 一种早期结直肠癌诊断标志物circ3823及其应用 | |
JP7560112B2 (ja) | Pvaスポンジを用いるリキッドバイオプシーの調製方法 | |
Budowle et al. | Population studies on three Native Alaska population groups using STR loci | |
US20110311981A1 (en) | Method of determining lymph node metastasis in a lung cancer, apparatus for determining lymph node metastasis in a lung cancer, and computer program product | |
Zhong et al. | Increased levels of CK19 mRNA in oral squamous cell carcinoma tissue detected by relative quantification with real-time polymerase chain reaction | |
WO2024111617A1 (ja) | 皮膚表上脂質検体内部標準遺伝子 | |
JP7498738B2 (ja) | 皮脂rna情報のデータ均質化方法 | |
KR102346184B1 (ko) | 피부 보습 위험도 예측용 바이오마커 및 이의 용도 | |
CN110592221A (zh) | 一种早期结直肠癌诊断标志物circ4953及其应用 | |
KR102720023B1 (ko) | 바이설파이트 변환 평가용 키트 및 이를 이용한 평가 방법 | |
WO2021230380A1 (ja) | Rna情報のデータ処理方法 | |
CN115927607B (zh) | 生物标志物在胃癌诊断中的应用 | |
JP2023069413A (ja) | 被膜の皮膚保湿効果の評価方法 | |
JP2023073134A (ja) | ホットフラッシュの検出方法 | |
JP2023073135A (ja) | 更年期障害の重症度の検出方法 | |
JP2023069499A (ja) | 乾燥による皮膚表面形状悪化の検出方法 | |
KR20230040069A (ko) | 바이설파이트 변환 평가용 키트 및 이를 이용한 평가 방법 | |
WO2022186297A1 (ja) | アトピー性皮膚炎による皮膚痒みの症度悪化の検出方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22816124 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280039127.7 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022816124 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022816124 Country of ref document: EP Effective date: 20240102 |